Genentech, Incorporated, 1 DNA Way, South San Francisco, CA 94080, USA.
Trends Pharmacol Sci. 2009 Dec;30(12):624-30. doi: 10.1016/j.tips.2009.09.004.
Identification and characterization of VEGF as an important regulator of angiogenesis, and FDA approval of the first anti-angiogenic drugs, has enabled significant advances in the therapy of cancer and neovascular age-related macular degeneration. However, similar to other therapies, inherent/acquired resistance to anti-angiogenic drugs may occur in patients, leading to disease recurrence. Recent studies in several experimental models suggest that tumor and non-tumor (stromal) cell types may be involved in the reduced responsiveness to the treatments. The present review examines the role of tumor- as well as stromal cell-derived pathways involved in tumor growth and in refractoriness to anti-VEGF therapies.
鉴定和阐明 VEGF 作为血管生成的重要调控因子，以及美国食品和药物管理局批准第一种抗血管生成药物，使得癌症和新生血管性年龄相关性黄斑变性的治疗取得了显著进展。然而，与其他疗法一样，患者可能会对抗血管生成药物产生内在/获得性耐药，从而导致疾病复发。几项实验模型的最近研究表明，肿瘤和非肿瘤（基质）细胞类型可能参与了对治疗的反应降低。本综述探讨了肿瘤和基质细胞来源的通路在肿瘤生长和抗 VEGF 治疗耐药性中的作用。
